Identification of a Novel Deep Intronic Variant by Whole Genome Sequencing Combined With RNA Sequencing in a Chinese Patient With Menkes Disease

Xiufang Zhi1,2†, Qi Ai3,4†, Wenchao Sheng1,2†, Yuping Yu1,2†, Jianbo Shu2,5,6, Changshun Yu7, Xiaoli Yu2,8*, Dong Li2,8* and Chunquan Cai2,5,6*

1Graduate College of Tianjin Medical University, Tianjin, China, 2Tianjin Children’s Hospital (Children’s Hospital of Tianjin University), Tianjin, China, 3Key Laboratory of Cancer Prevention and Therapy, Department of Pediatric Oncology, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China, 4Department of Hematology and Oncology, Tianjin Children’s Hospital, Tianjin, China, 5Tianjin Pediatric Research Institute, Tianjin, China, 6Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China, 7Tianjin Kingmed Center for Clinical Laboratory, Tianjin, China, 8Department of Neurology, Tianjin Children’s Hospital, Tianjin, China

Background: Menkes disease (MD) is a rare X-linked connective tissue disorder of copper metabolism caused by pathogenic variant(s) in ATP7A gene. The aim of the present study is to determine the clinical characteristics and molecular basis of one patient with MD.

Methods: One 10-month-old Chinese boy who met the clinical manifestations of MD was enrolled in this study. Whole genome sequencing (WGS) was performed in the patient in order to identify the variant(s), followed by Sanger sequencing. RNA sequencing (RNA-seq) from whole blood was subsequently applied to assess the effect of variant on transcription levels, and reverse transcriptase-polymerase chain reaction (RT-PCR) was performed for further validation. In addition, X chromosome inactivation (XCI) status of the patient’s mother at the DNA level was measured by capillary electrophoresis.

Results: The patient suffered from intermittent convulsions for more than 6 months, with psychomotor retardation and neurodegenerations. The patient also had curly hair, hypopigmented skin, cutis laxa, decreased muscle strength and hypotonia. MRI showed the intracranial arteries were tortuous with some “spiral” changes. The patient’s serum ceruloplasmin level was low. WGS revealed one novel hemizygous variant, c.2627-501C>T (NM_000052.7), located in the deep intronic sequence of ATP7A gene. Sanger sequencing confirmed that the variant was inherited from his mother. RNA-seq confirmed the variant itself, and identified a pseudo-exon inserted between exons 12 and 13 in mRNA of ATP7A. The sequencing results of RT-PCR from the patient confirmed this finding, while neither of his parents detected aberrant splicing. The Capillary electrophoresis results showed that the patient’s mother had a skewed XCI.

Conclusion: Our finding of the variant enlarges the variant spectrum in the ATP7A gene. This is a novel deep intronic variant which leads to the activation of a pseudo-exons in the ATP7A gene, and it demonstrates the usefulness of WGS combined with RNA-seq, in terms of revealing disease-causing variants in non-coding regions. Furthermore, the fact
INTRODUCTION

MD, also known as Menkes kinky hair syndrome, is a rare X-linked recessive genetic disease of impaired copper metabolism caused by variants in ATP7A gene (Caicedo-Herrera et al., 2018; Patel et al., 2017). Clinical manifestations include neurological symptoms and systemic multi-system dysfunction (Altarelli et al., 2019). According to clinical manifestations and progression, it can be divided into three subtypes: 1) classical type accounts for 90–95%, manifested as progressive neurodegeneration, seizures, connective tissue abnormalities and “kinky” with hair, and ultimately death in early childhood; 2) atypical MD has various clinical phenotypes of the classical type, but the degree is milder and the survival time is longer; and 3) occipital horn syndrome only affects connective tissue and bones, with the mildest form (Bonati et al., 2017; Kaler and Distasio, 1993; Kodama et al., 2012; Smopoku et al., 2015).

ATP7A gene, located on the Xq13.3 chromosomal region, contains 23 exons and encodes the transmembrane P-type ATP enzyme which can transport copper to the extracellular or Golgi apparatus by phosphorylation/dephosphorylation (Hartwig et al., 2019; Horn and Wittung-Stafshede, 2021; Skjorringe et al., 2017). Variants in ATP7A gene cause the inactivation of copper transport ATP enzyme, which block the absorption of copper in intestinal mucosa and the transport of copper across blood-brain barrier, ultimately leading to nervous system abnormalities and multi-system dysfunction (Chen et al., 2020; Maung et al., 2021; Petris et al., 2000; Prithvi et al., 2019). MD is mostly caused by nonsense variants, frame shift variants and splice site variants (Cao et al., 2017; de Gemmis et al., 2017; Kaler et al., 2020; Tumer, 2013). About 22% of ATP7A variants are splice site variants (Moller et al., 2009). Splice site variants may cause one or more exons complete skipping or retention of introns by activation of cryptic splice sites within exons or introns (Anna and Monika, 2018; Parada et al., 2014), and eventually affect the structure and function of transmembrane P-type ATP enzyme or reduce the expression of normal proteins (Moller et al., 2000). In the clinically discovered ATP7A variant-related MD patients, the vast majority of splice site variants occur in the intrinsic splicing zone (Skjorringe et al., 2011). The pathogenesis of deep intronic variants is rarely reported.

One possible important reason why deep intronic variants are always overlooked is that the detection methods are inappropriate. As an important means of identify disease-causing genetic variants of individuals affected with a genetically undiagnosed rare disorder, the main disadvantage of whole exome sequencing (WES) is that it cannot indicate disease-causing variants in non-coding regions. WGS in principle reveals all genetic variants, however, the main challenges are the sizeable variants number and poor interpretation of the non-coding variants. RNA-seq can directly detect gene expression, which help to reveal splice defects, the mono-allelic expression of heterozygous loss-of-function variants, and expression outliers, thereby providing functional data to support the clinical interpretation of variants (Cummings et al., 2017; Kremer et al., 2017). Therefore, the combination of WGS and RNA-seq displays strong superiority in the detection and analysis of non-coding variants.

In the present study, we identified a novel hemizygous variant of ATP7A located in deep intronic sequences by WGS combined with RNA-seq in a Chinese family. In addition, we described the clinical profile, laboratory and radiological findings of the patient and performed a variant analysis of ATP7A in the patient with MD.

Keywords: ATP7A gene, Menkes disease, whole genome sequencing, RNA sequencing, deep intronic variants

Patients, Materials and Methods

Ethics Statement

The study was approved by the Ethics Committee of Tianjin Children’s Hospital (Tianjin University Children’s Hospital), and the study approval reference number was 2016021. Written informed consent of the patient was obtained from his parents, and the parents gave their own written informed consent to take part in this study. All study procedures adhered to the tenets of the Declaration of Helsinki.

Patients

The patient, a 10-month-old Chinese boy with non-consanguineous parents, was admitted to Tianjin Children’s Hospital because of convulsions. All of the patient’s clinical information was collected from medical records. The peripheral blood samples were collected from the patient and his parents. All the experiments performed with human materials were in accordance with the relevant guidelines and regulations.

DNA and RNA Isolation

Genomic DNA was isolated from peripheral venous blood of the patient and both parents using Blood Genomic DNA Mini Kit (CWBIO, Jiangsu, China) according to the manufacturer’s protocol. Total RNA was extracted from peripheral venous blood using Lymphocyte Separation Medium (SOLARBIO SCIENCE &TECHNOLOGY CO., LTD., Beijing, China) and Trizol reagent (TIANGEN BIOTECH CO., LTD., Beijing, China). DNA and RNA was quantified by Nanodrop Spectrophotometer (THERMO FISHER SCIENTIC, Shanghai, China). DNA and blood samples were stored at −20°C. RNA was stored at −80°C.

WGS and in Silico Analysis of Potential Splice Variant

WGS was performed by KingMed company (Guangzhou, China) on the patient. The DNA was performed with 150-bp paired-end sequencing and average coverage of 50-fold in more than 95% of...
the target regions, including the coding region and intronic region. WGS data were processed following the standard procedure. Low-quality reads, adapters, and sequences with more than 5% unknown bases were removed from the raw reads. Sequenced reads were aligned to the human reference genome hg19 using the Burrows-Wheeler Aligner software. Duplications were marked with Picard and BAM was sorted with Samtools2. GATK Best Practices Pipeline was used in the process of SNP and INDEL calling. SNPs and INDELs were annotated using Annovar and local software. The HGMD, 1,000 genomes, OMIM, dbSNP, Clinvar and local database were used for variants annotation. Specifically, all the variants were firstly filtered using the dbSNP, 1,000 genomes, and local databases, deleting all variants with frequency ≥1% in the population. All the remaining filtered variants were searched in the OMIM and HGMD databases for identifying the variants of genes associated with the disease phenotype. Then, the variant pathogenicity classification followed the variant classification criteria formulated by American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) (Richards et al., 2015; Zhang et al., 2020). Clinical significance grading was done as described previously (Cai et al., 2021). Sanger sequencing was performed for the candidate variant(s) in the patient and his parents for confirmation.

To analyze the effect of the candidate variant(s) on pre-mRNA splicing, we performed in silico analysis using several different freely available software including NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/), Splice Site Prediction by Neural Network (www.fruitfly.org/seq_tools/splice.html), and ASSP model (wangcomputing.com/assp). The variant(s) designations were based on ATP7A gene (NM_000105.2) from NCBI, and the gene sequence is from NC_000023.11. We analyzed the new splice site and its effect on splicing by comparing the difference of the splice site between the wild type and the variant(s).

RNA-Seq
RNA-seq assay was applied to confirm the splicing effect of the candidate variant(s). Whole-blood samples were collected in PAXgene whole blood RNA tubes (BD), and intracellular RNA was extracted using PAXgene blood RNA kit (QIAGEN) according to the manufacturer’s recommendation. RNA was quantified and then processed to sequencing library preparation using Ribo-off rRNA depletion kit (human/mouse/rat) and VAHTS universal V8 RNA-seq library prep kit for Illumina (Vazyme). The qualified library was sequenced on an Illumina Novaseq 6,000 platform with PE150 mode at the Tianjin KingMed Center for Clinical Laboratory for Translational Genomics, and approximately 30–50 million raw reads were expected to be generated.

Raw reads were processed by trimming poly-A/T stretches and Illumina adapters using Cutadapt software and resulting reads shorter than 30bp were discarded. Sequencing data was mapped to the GRCh37 reference genome using STAR and HISAT2 software with default parameters. Transcripts were assembled by Stringtie software from the reads alignment data for abnormal transcripts detection. The IGV v2.9.4 software was applied for manual analysis for the genomic regions of interest.

RT-PCR
Complementary DNAs (cDNA) were synthesized with the FastKing RT Kit (With gDNase) (TIANGEN BIOTECH CO.LTD., Beijing, China) according to the manufacturer's instruction. To determine the consequence of the variant for the ATP7A gene transcript, we performed PCR experiments on cDNA using primers located in exon 9 (Forward, 5′-CTTCTCTGTGTTGCG-3′) and in exon 15 (Reverse, 5′-ATCGTTTCTGTTCGGGAGG-3′). Due to the low expression of ATP7A in whole blood, we performed two sequential amplification reactions was used as the template for the second PCR, which was amplified by the same primers as the first primer pair. The final PCR products from cDNA was resolved by 1.5% agarose gel electrophoresis and sequenced (GENEWIZ, Hangzhou, China).

XCI Status Measurement by the Human Androgen Receptor (HUMARA) Assay
The XCI status at the DNA level was measured using HUMARA assay based on the highly polymorphic CAG trinucleotide repeat in the promoter area of the androgen receptor (AR). Specifically, genomic DNA was digested with methylation-sensitive restriction endonuclease Hhal (TAKARA BIO, Japan). The CAG repeat regions from digested and undigested DNA samples were amplified by PCR with forward primer (GCT GTGAAGGTGTGCTTCCCTCAT) and reverse primer (TCCAGAATCTGTTC CAGAGCGTGC) (Pan et al., 2021), then the PCR products were resolved by 1.5% agarose gel electrophoresis to confirm that DNA had been fully digested. Additionally, the same DNA samples were amplified by PCR using same primers but the forward primer was end-labeled with FAM fluorescence. The products were analysed by capillary electrophoresis (BECKMAN COULTER, United States). The proportion of variant allele on the inactive X chromosome was calculated according to the standard formula (Thouin et al., 2003). XCI status was classified as random (XCI<70%), or skewed (XCI≥70%) (Pu et al., 2010; Sato et al., 2004). If the ratio was ≥90%, the XCI pattern was considered to be extremely skewed (Yoon et al., 2008).

RESULTS
Clinical Characteristics of the Patient
The male Chinese patient (proband) was born at term after an uncomplicated pregnancy, with third degree contamination of amniotic fluid, and neonatal jaundice after birth. His birth weight was 2.25 kg. Convulsions were seen as early as 4 months after birth, the patient presented with right-sided eyelid myoclonus for several seconds over 10 times a day. The second seizure type appeared at 6 months of age. The patient showed flexor spasms in either a isolation seizure or a cluster of seizures. When a cluster of seizures occurred, seizure occurred 2–8 times per day and the maximum duration was about 20 s. At 8 months of age, the third
type, generalized tonic-clonic seizures, occurred. The patient received 7–8 times of seizure per day, each lasting for 30 s to 1 min. There were no loss of consciousness in the first two types of seizure. Only spasms were described in the last 1 month with an exacerbation of symptoms. The patient received antiepileptic therapy with topiramate and levetiracetam, but the effect was poor. At present, the patient weighed 7.1 kg. Developmental milestones of the patient was normal before 4 months of age. However, developmental regression was beginning to appear at 4 months of age. The age of the patient was 10.6 months old at this visit. He could not raise his head, turn over, or sit alone. His deciduous teeth had not erupted yet. He could not make a laugh and sought to track parallax. He could only eat with a dropper at presentation, showing global developmental delay.

On physical examination, his head was flat with irregular shape. The hair was sparse, short, and curly while the skin was fair, rough, and loose. One 3 mm × 3 mm café au lait spot could be seen on the inside of the right upper arm. He had pectus excavatum, decreased muscle strength, hypotonia and decreased muscle volume.

Video EEG showed hypsarrhythmia. Brain MRI showed patchy flaky slightly long T2 signal in the white matter of bilateral frontal, temporal, and parietal cortices. DWI showed a small patch hyperintensity in the bilateral centrum semiovale. Moreover, MRI showed widened ventricles, sulci and cisterns. Brain MRA showed the intracranial arteries were tortuous with some “spiral” changes (Figure 1A). The serum ceruloplasmin was 0.05 g/L (normal range 0.15–0.30 g/L). MD was suspected clinically. Given the severe neurological symptoms, it was considered to be the classical type. An extensive previous genetic workup, including karyotype, WES, trio WES, were negative.

Identification and Analysis of the Candidate Variant
140G sequencing data was acquired after WGS for the proband and 40.5 million SNVs, 931 thousands indels, and no pathogenic CNVs were detected in the proband’s WGS data. After variant pathogenicity classification and clinical significance grading screening process, only one candidate variant, NC_000023.10: g.77275240 C>T (hg37, chrX), c.2627-501C>T (NM_000052.7), located in deep intron 12 of ATP7A gene was identified in the sequencing data as a potential causative variant for the proband’s phenotype. Sanger sequencing confirmed that the c.2627-501C>T variant was inherited from the mother carrying heterozygous variant (Figure 1B). This variant has never been reported in ClinVar database, HGMD database, or gnomAD database before. We submitted the sequence of the interest region to splice site predictor programs (NetGene2, Splice Site...
Prediction by Neural Network, ASSP model) and all of them confirmed that the variant activated a new splice donor site (Figure 1C).

**Aberrant Splicing Caused by the Varant in Transcription Level**

8.8G sequencing data was acquired after RNA-seq for the proband. The ATP7A gene region was carefully looked through manually using the IGV software and we successfully detected the c.2627-501C > T variant. The data also demonstrated clearly an abnormal splicing pattern that resulted in an out-of-frame pseudo-exon between exons 12 and 13 (Figure 2A) which predicted to cause frame shift and protein truncation (p. Gly876Cysfs*26). By the way, the sequencing depth for the c.2627-501C site was only 5x and variants with such low depth were rendered as too much low quality data (although the C > T mutation frequency was 5/5) and were filtered after variant calling with default parameters. For further verification of the impact of the novel variant on splice site, we performed RT-PCR. In agarose gel electrophoresis of RT-PCR, cDNA analysis revealed a lager product size in patient compared with the normal size of his parents (Figure 2B). Direct sequencing of the patient’s amplified fragment revealed aberrant RNA splicing effect.
between exons 12 and 13, which resulted in the appearance of a pseudo-exon in the splicing process (Figure 2C), which was consistent with the RNA-seq result in terms of variant analysis. Of note, only wild-type (WT) ATP7A mRNA expression was detected in both electrophoresis and direct sequencing in the patient’s mother.

**Pathogenic Classification of the Variant**

According to the ACMG/AMP variant classification criteria, the c.2627-501C > T variant could be classified as 'likely pathogenic' (PP4-Moderate, PS3-Moderate, PM2-Supporting, PP3-Supporting) (Richards et al., 2015; Zhang et al., 2020).

**Evaluation of XCI**

Given that only WT ATP7A mRNA expression was detected in the patient’s mother, we performed the HUMARA assay for XCI on samples from the patient and his parents to evaluate the XCI state and to better understand the mechanism. The results of agarose gel electrophoresis showed that the DNA was completely digested (Figure 3A). The results of capillary electrophoresis show...
showed that there was one patient’s product with a size of 292 bp before DNA digestion, suggesting that this was the X chromosome carrying the variant (Figure 3B). There were two mother’s products, 272 bp (WT) and 292 bp (variant), both in completely digested DNA and undigested DNA (Figure 3B). The proportion of variant allele on the inactive X chromosome was calculated as 78.0% indicating a skewed XCI model compare with 45.3% in normal female control.

DISCUSSION

In this study, the patient presented with epilepsy, rough and loose skin, sparse and curly hair, and psychomotor retardation. The level of serum ceruloplasmin was low. Otherwise, the patient’s MRI showed that the intracranial arteries were tortuous with some “spiral” changes. All the above manifestations were highly matched with MD. The complete diagnosis of MD still required genetic variant evidence. As a result, the patient and his parents underwent WES, trio WES in other medical institution, but no abnormality consistent with the patient’s clinical manifestations was found. Considering the limitations of WES including the inability to detect non-coding variants in intronic regions (Burdick et al., 2020; Jelin and Vora, 2018) and balanced translocation of chromosomes, we performed a karyotype analysis for the patient and the chromosomal analysis revealed a normal karyotype with 46, XY.

Due to these negative results and strong demands from the patient’s parents to find the etiology of the disease, we performed WGS for its capability to detect a full range of common and rare genetic variants of different types across almost the entire genome (Lappalainen et al., 2019). WGS found a deep intronic variant in the patient’s ATP7A gene (c.2627-501C>T). Then, the Sanger sequencing found that the variant was inherited from his mother.

It has been reported that deep intronic variant results in intron fragments (also known as cryptic exons or pseudo-exons) being inserted into mature transcripts, and leads to frame shift or premature termination of translation (Anna and Monika, 2018). Functionally, these variants create new acceptor or donor sites, which are recognized by the splicing complex and interact with existing intron cryptic splice sites. It is also possible that deep intronic variants lead to the generation of new regulatory elements (such as splicing enhancers) and the recognition of specific introns. To explore the effect of the variant on transcription level, we performed RNA-seq. RNA-seq can directly detect gene expression and provide functional data that supports clinical interpretation of variants. Although RNA-seq is a supplementary tool, its advantage lies in detecting the functional consequences of DNA variants that affect splicing and gene expression levels. Therefore, it supports the interpretation of variants of uncertain significance, and reordered variants that are ignored by DNA sequencing. The combination of RNA-seq with WES or WGS analysis may provide more information than WES or WGS analysis alone (Fresard et al., 2019; Gonorazky et al., 2019; Lee et al., 2020). In our case, based on the guidance of WGS to find the causative deep intronic variants, RNA-seq analysis found abnormal gene expression and splicing. RNA-seq result of the patient showed that a pseudo-exon (88bp) from intron 12 located between exons 12 and 13 was contained in the mature mRNA, and confirmed by RT-PCR. Due to the variant, a new donor splice site was generated, and the upstream cryptic splice acceptor site was activated, leading to 88 bp insertion from the new donor splice site upstream in intron 12 (Figure 2D). Finally, a pseudo-exon fragment from intron 12 was included in the mature mRNA, which resulted in a frame shift and a premature termination codon (p. Gly876Cysfs*26). A deep intron c.3718-2477C>T variant located in intron 19 of CFTR gene has been reported in the literature. This variant leads to the generation of a new donor site, resulting in an 84 bp pseudo-exon containing into the mature mRNA. This pseudo-exon contains an in-frame termination codon, so the translated protein is shorter and non-functional (Anczukow et al., 2012; Anna and Monika, 2018). However, there is a limitation in our study. At present, we cannot explain the mechanisms of how the newly formed donor splice site and cryptic acceptor splice site caused by the deep intronic variant lead to aberrant splicing. We will further verify these issues in follow-up research.

In this study, it was learned through WGS and Sanger sequencing that the patient’s variant was inherited from his mother, but the subsequent RT-PCR results showed that only WT ATP7A mRNA expression was detected in the patient’s mother, which was same with that of the father’s. We performed the HUMARA assay for XCI and the result suggested that the patient’s mother had a skewed XCI with a preferential inactivation of the X chromosome that carried the variant allele. This result may explain why the patient’s mother could only detect WT ATP7A mRNA expression.

Due to the high mortality rate of MD, patients with classic MD generally die before the age of three. Early diagnosis of MD and identification of pathogenic variants are the basis of genetic counseling. The results of this study are of great significance for this family’s genetic counseling, preventing the birth of children with MD (Elliott, 2020; Perge and Igaz, 2019; Yang and Kim, 2018). Early diagnosis may also be meaningful for MD gene therapy. It has been reported that Antisense oligonucleotides can improve the abnormal splicing effect of the aforementioned BRCA2 gene intron 12, c.6937 + 594T > G to a certain extent (Anczukow et al., 2012). Gene therapy is still in the exploratory stage, however, it is expected that MD caused by such splice site variants can be treated by gene therapy in the future.

CONCLUSION

Our finding of the variant enlarges the variant spectrum in the ATP7A gene. This is a novel deep intronic variant which leads to the activation of a pseudo-exons in the ATP7A gene, and it demonstrates the usefulness of WGS combined with RNA-seq, in terms of revealing disease-causing variants in non-coding regions. Furthermore, the fact that the deep intronic variants
cause disease by the activation of pseudo-exon inclusion indicates that this might be an important mechanism in MD.

DATA AVAILABILITY STATEMENT

All data relevant to the study are included in the article. The whole-genome sequencing data are not publicly available as these could compromise research participant privacy. Specific variant requests or other data are available from the corresponding author CC upon reasonable request.

ETHICS STATEMENT

The study was approved by the Ethics Committee of Tianjin Children’s Hospital (Tianjin University Children’s Hospital), and the study approval reference number was 2016021. Written informed consent of the patient was obtained from his parents, and the parents gave their own written informed consent to take part in this study. All study procedures adhered to the tenets of the Declaration of Helsinki.

REFERENCES

Altarelli, M., Ben-Hamouda, N., Schneider, A., and Berger, M. M. (2019). Copper Deficiency: Causes, Manifestations, and Treatment. *Natr. Clin. Pract.* 34 (4), 504–513. doi:10.1002/ncc.10328

Anczuków, O., Buisson, M., Léoné, M., Coutanson, C., Lasset, C., Calender, A., et al. (2012). BRCA2 Deep Intronic Mutation Causing Activation of a Cryptic Exon: Opening toward a New Preventive Therapeutic Strategy. *Clin. Cancer Res.* 18 (18), 4903–4909. doi:10.1158/1078-0432.CCR-12-1100

Anna, A., and Monika, G. (2018). Splicing Mutations in Human Genetic Disorders: Examples, Detection, and Confirmation. *J. Appl. Genet.* 59 (3), 253–268. doi:10.1007/s13353-018-0444-7

Bonati, M. T., Verde, F., Hladnik, U., Cattelan, P., Campana, L., Castronovo, C., et al. (2017). A Novel Nonsense ATP7A Pathogenic Variant in a Family Exhibiting a Variable Occipital Horn Syndrome Phenotype. *Mol. Genet. Metab. Rep.* 13, 14–17. doi:10.1016/j.ymgmr.2017.07.007

Burdick, K. J., Cogan, J. D., Rives, L. C., Robertson, A. K., Kozuira, M. E., Brokamp, E., et al. Undiagnosed Diseases Network (2020). Limitations of Exome Sequencing in Detecting Rare and Undiagnosed Diseases. *Am. J. Med. Genet. A* 182 (6), 1400–1406. doi:10.1002/ajmg.a.61558

Cai, C., Yu, C., and Shu, J. (2021). Recommendations on the Clinical Significance Grading of Genetic Variation in Clinical Gene Testing. *Tianjin Med. J.* 49 (6), 561–569.

Caicedo-Herrera, G., Candelo, E., Pinilla, J. F., Vidal, A., Cruz, S., and Pachajoa, H. (2018). Novel ATP7A gene Mutation in a Patient with Menkes Disease. *TigG* Vol. 11, 151–155. doi:10.2147/TAGC.S180087

Cao, B., Yang, X., Chen, Y., Huang, Q., Wu, Y., Gu, Q., et al. (2017). Identification of Novel ATP7A Mutations and Prenatal Diagnosis in Chinese Patients with Menkes Disease. *Metab. Brain Dis.* 32 (4), 1123–1131. doi:10.1007/s11011-017-9985-4

Chen, J., Jiang, Y., Shi, H., Peng, Y., Fan, X., and Li, C. (2020). The Molecular Mechanisms of Copper Metabolism and its Roles in Human Diseases. *Pflugers Arch.* - *Eur. J. Physiol.* 472 (10), 1415–1429. [Journal Article; Research Support, Non-U.S. Gov’t; Review]. doi:10.1007/s00424-020-02412-2

Cummings, B. B., Marshall, J. L., Tukiainen, T., Lek, M., Donkervoort, S., Foley, A. R., Bolduc, V., Waddell, L. B., Sandaradura, S. A., O’Grady, G. L., Estrella, E., Reddy, H. M., Zhao, F., Weisburd, B., Karczewski, K. J., O’Donnell-Luria, A. H., Birnbaum, D., Sarkozy, A., Hu, Y., Goronzy, V., Hlaeys, K., Joshi, H., Bournazos, A., Oates, E. C., Ghassou, R., Davis, M. R., Laing, N. G., Topf, A., Kang, P. B., Beggs, A. H., North, K. N., Straub, V., Dowling, J. J., Muntoni, F., Clarke, N. F., Cooper, S. T., Bönne mann, C. G., and MacArthur, D. G. Genotype-Tissue Expression Consortium (2017). Improving Genetic Diagnosis in Mendelian Disease with Transcriptome Sequencing. *Sci. Transl. Med.* 9 (386). [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t]. doi:10.1126/scitranslmed.aal5209

de Gemmis, P., Enzo, M. V., Lorenzetto, E., Cattelan, P., Segat, D., and Hladnik, U. (2017). 13 Novel Putative Mutations in ATP7A Found in a Cohort of 25 Italian Families. *Metab. Brain Dis.* 32 (4), 1173–1183. doi:10.1007/s11011-017-0010-8

Elliott, A. M. (2020). Genetic Counseling and Genome Sequencing in Pediatric Rare Disease. *Cold Spring Harb Perspect. Med.* 10 (3), a036652. doi:10.1101/cshperspect.a036652

Frédard, L., Smail, C., Smail, C., Ferraro, N. M., Teran, N. A., Li, X., Smith, K. S., Bonner, D., Kernohan, K. D., Marwaha, S., Zappala, Z., Balliu, B., Davis, J. R., Liu, B., Prybol, C. J., Kohler, J. N., Zastrow, D. B., Reuter, C. M., Fisk, D. G., Grove, M. E., Davidson, J. M., Hartley, T., Joshi, R., Strober, B. J., Ultrameruer, S., Lind, L., Ingelsson, E., Battle, A., Bejerano, G., Bernstein, J. A., Ashley, E. A., Boycott, K. M., Merker, J. D., Wheeler, M. T., and Montgomery, S. B. Undiagnosed Diseases Network; Care4Rare Canada Consortium (2019). Identification of Rare-Disease Genes Using Blood Transcriptome Sequencing and Large Control Cohorts. *Nat. Med.* 25 (6), 911–919. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t]. doi:10.1038/s41591-019-0457-8

Gonorazky, H. D., Naumenko, S., Ramani, A. K., Nelakuditi, V., Mashouri, P., Wang, P., et al. (2019). Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease. *Am. J. Hum. Genet.* 104 (3), 466–483. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t]. doi:10.1016/j.ajhg.2019.01.012

Hartwig, C., Zlatic, S. A., Wallin, M., Vraals-Mortimer, A., Fahni, C. J., and Faundez, V. (2019). Trafficking Mechanisms of P-type ATPase Copper Transports. *Curr. Opin. Colloq.* 59, 24–33. [Journal Article; Research Support, N.I.H., Extramural; Review]. doi:10.1016/j.coch.2019.02.009

Horn, N., and Wittung-Stafshede, P. (2021). ATP7A-Regulated Enzyme Metatlation and Trafficking in the Menkes Disease Puzzle. *Biomedicines* 9 (4), 391. [Journal Article; Review]. doi:10.3390/biomedicines9040391

Jelin, A. C., and Vora, N. (2018). Whole Exome Sequencing. *Obstet. Gynecol.* 17. doi:10.3390/biomedicines9040391

Kaler, S. G., and DiStasio, A. T. (1993). ATP7A-Related Copper Transport Disorders. [Review; Book Chapter]

Kaler, S. G., Ferreira, C. R., and Yam, L. S. (2020). Estimated Birth Prevalence of Menkes Disease and ATP7A-Related Disorders Based on the Genome

AUTHOR CONTRIBUTIONS

DL and CC conceived the project. XZ drafted the manuscript. JS designed the experiments. WS, YY, QA, and CY performed the experiments and analyzed the data. XY provided patient care and relevant clinical information. All authors read, critically reviewed, and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China [grant number 81771589] and the Public Health and Technology project of Tianjin [grant number TJWJ2021ZD007].

ACKNOWLEDGMENTS

We thank patient and his parents for their participation in this study.
